title: Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
abstract: OBJECTIVE
  This analysis investigates incidence and time course of rash in the EURTAC study.
  
  
  METHODS
  Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.
  
  
  RESULTS
  Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.
  
  
  CONCLUSIONS
  Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
authors: Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
authors: Filippo
authors: F
authors: de Marinis
authors: Alain
authors: A
authors: Vergnenegre
authors: Antonio
authors: A
authors: Passaro
authors: Catherine
authors: C
authors: Dubos-Arvis
authors: Enric
authors: E
authors: Carcereny
authors: Ana
authors: A
authors: Drozdowskyj
authors: Ali
authors: A
authors: Zeaiter
authors: Pablo
authors: P
authors: Perez-Moreno
authors: Rafael
authors: R
authors: Rosell
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors
keywords: EGFR; erlotinib; non-small-cell lung cancer; rash; safety